Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Inclusion Criteria:

• Be at least 18 years of age

• Be diagnosed with cancer

• Have stable disease or no evidence of disease

• Report WORST level of fatigue in the past week as moderate to severe (i.e., a score >= 4 on a 0-10 scale, screening measures, question 1)

• Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) 2 or more months prior toenrollment. Participants currently receiving oral maintenance, targeted, or hormonaltherapy are eligible. Participants receiving intravenous supportive therapy (e.g.,bisphosphonates) are eligible

• Able to read and speak English

• Currently not pregnant or breastfeeding. Women of child-bearing potential must agreeto use adequate contraception, i.e, abstinence, IUD (intrauterine device), hormonalcontraceptive (birth control pills) or barrier method (condoms) prior to study entryand for the duration of study participation

• Be capable of providing written informed consent

Exclusion Criteria:

• Be receiving intravenous anti-cancer therapy (e.g., intravenous immune checkpointinhibitor therapy, targeted therapy)

• Be currently taking any medications that contain bupropion (e.g., Wellbutrin,Forfivo, Aplenzin, or Zyban)

• Be taking an monoamine oxidase inhibitor (MAOI), linezolid, or methylene blue withintwo weeks prior to enrollment

• Be taking any anti-psychotic medications within a week prior to enrollment

• Have a history of renal impairment (i.e., glomerular filtration rate < 45)

• Have a history of cirrhosis (i.e., Child-Pugh score >= 5)

• Have a history of seizures

• Have a history of bulimia or anorexia nervosa

• Report a history of sensitivity to bupropion

• Report an allergy to lactose

• Have psychiatric or neurological disorder(s) that would interfere with studyparticipation per physician or physician's designee